Details

Autor(en) / Beteiligte

• Peng, Yong
• Qin, Di
• Wang, Yudi
• Xue, Lian
• Qin, YaXuan
• Xu, Xin

Titel

The effect of SGLT-2 inhibitors on cardiorespiratory fitness capacity: A systematic review and meta-analysis

Ist Teil von

• Frontiers in physiology, 2023-01, Vol.13, p.1081920-1081920

Ort / Verlag

Switzerland: Frontiers Media S.A

Erscheinungsjahr

2023

Quelle

EZB Electronic Journals Library

Beschreibungen/Notizen

• The study aimed to evaluate the effect of sodium-glucose transporter 2 (SGLT-2) inhibitors on various parameters of exercise capacity and provide an evidence-based basis for type 2 diabetes mellitus (T2DM) combined with heart failure (HF) patients or HF patients without T2DM who use SGLT-2 inhibitors to improve cardiorespiratory fitness (CRF). According to the participant, intervention, comparison, and outcome (PICO) elements, the effects of SGLT-2 inhibitor administration on VO or VO peak were researched in this study. Weighted mean difference (WMD) and 95% confidence intervals (CIs) were calculated (random-effects model). Heterogeneity was assessed by the I test. Six studies were included according to the eligibility criteria: four were RCTs, and two were non-RCTs. Compared with the control group, the merge results of RCTs showed that SGLT-2 inhibitors could significantly increase the VO peak (WMD, 2.02 ml kg min , 95% CI: 0.68-3.37, and = 0.03; I = 0% and = 0.40) and VAT (WMD, 1.57 ml kg min , 95% CI: 0.06-3.07, and = 0.04; I = 0% and = 0.52) of the obese population, patients with T2DM, and chronic HF patients with or without T2DM. Subgroup analysis showed that SGLT-2 inhibitors improved the VO peak in non-HF patients (WMD, 3.57 ml kg min , 95% CI: 0.87-6.26, and = 0.009; I = 4% and = 0.31) more than in HF patients (WMD, 1.46 ml kg min , 95% CI: -0.13-3.04, and = 0.07; I = 0% and = 0.81). Moreover, the merge of single-arm studies also indicated that empagliflozin could improve VO peak (MD, 1.11 ml kg min , 95% CI: 0.93-1.30, and = 0.827, Δ = 0.000 and I = 0%) of T2DM patients with chronic HF. Despite the limited number of studies and samples involved, the meta-analysis preliminarily demonstrated that SGLT-2 inhibitors could improve some parameters of exercise capacity (VO peak, VAT) in chronic HF patients with or without T2DM and obese individuals, which had a positive effect on promoting cardiopulmonary fitness to help these populations improve their prognosis. [https://www.crd.york.ac.uk/prospero/#recordDetails], identifier [CRD42020202788].